Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Diagnostic conformity to who criteria and use of cytoreductive therapy in classical myeloproliferative neoplasms: Experience from a resource-limited country

View Full Paper
Ask AI
Bookmark
Share

Authors

SSS. SivakumaranVRV RatnamalalaLGLallindra Gooneratne

Discussion

Loading...

Member takes

Overview

Retrospective analysis highlights diagnostic uncertainty in classical MPN, with cytoreductive therapy frequently used despite risks.

Key Points

  • Hydroxycarbamide was administered to 80% of patients without fulfilling diagnostic criteria, leading to multiple complications.
  • A significant shortfall in diagnostic conformity was observed, particularly affecting polycythemia vera and primary myelofibrosis.
  • Retrospective cross-sectional descriptive study conducted in a resource-limited setting with 125 patients and various treatment responses.
  • Risk stratification was hindered by limited molecular data, emphasizing the need for improved access to genetic testing.

Cite This Study

Sivakumaran et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8eehttps://doi.org/10.1182/blood-2025-7324
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Access barriers and treatment patterns in Philadelphia-negative myeloproliferative neoplasms (Ph- MPN): Insights from a brazilian physician survey2025
  2. 2Treatment landscape and outcome of myeloproliferative neoplasms in asia: Interim analysis of the Asian myeloproliferative neoplasm registry2025
  3. 3Myelodysplastic/myeloproliferative overlap neoplasms: Clinicopathological features, treatment strategies, and outcomes — a UK multicentre cohort Study2025
  4. 4Myeloproliferative neoplasms-unclassifiable (MPN-U): A carefully curated series of 30 Mayo Clinic patients2025
  5. 5A large language model-based framework for automated phenotypic characterization in myeloproliferative neoplasms2025